Emerging therapies for diabetic macular edema

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

Original languageEnglish
Pages (from-to)163-171
Number of pages9
JournalExpert Review of Ophthalmology
Volume4
Issue number2
DOIs
StatePublished - Sep 14 2009

Fingerprint

Macular Edema
Blood pressure
Medical problems
Sugars
Blood
ruboxistaurin
Therapeutics
Temazepam
Light Coagulation
Vitrectomy
Vascular Endothelial Growth Factor A
Blood Glucose
Diabetes Mellitus
Adrenal Cortex Hormones
Randomized Controlled Trials
Blood Pressure

Keywords

  • Diabetic macular edema
  • Pars plana vitrectomy
  • Randomized clinical trial
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Emerging therapies for diabetic macular edema. / Schwartz, Stephen; Flynn, Harry W; Scott, Ingrid U.

In: Expert Review of Ophthalmology, Vol. 4, No. 2, 14.09.2009, p. 163-171.

Research output: Contribution to journalArticle

@article{6477abe0b1d24d73bfcdd3ab1af44a36,
title = "Emerging therapies for diabetic macular edema",
abstract = "Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.",
keywords = "Diabetic macular edema, Pars plana vitrectomy, Randomized clinical trial, Vascular endothelial growth factor",
author = "Stephen Schwartz and Flynn, {Harry W} and Scott, {Ingrid U.}",
year = "2009",
month = "9",
day = "14",
doi = "10.1586/eop.09.5",
language = "English",
volume = "4",
pages = "163--171",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Emerging therapies for diabetic macular edema

AU - Schwartz, Stephen

AU - Flynn, Harry W

AU - Scott, Ingrid U.

PY - 2009/9/14

Y1 - 2009/9/14

N2 - Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

AB - Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

KW - Diabetic macular edema

KW - Pars plana vitrectomy

KW - Randomized clinical trial

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=69949138495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949138495&partnerID=8YFLogxK

U2 - 10.1586/eop.09.5

DO - 10.1586/eop.09.5

M3 - Article

AN - SCOPUS:69949138495

VL - 4

SP - 163

EP - 171

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 2

ER -